AngioDynamics (ANGO) Tops Q4 EPS by 3c; Affirms FY18 Outlook

AngioDynamics (NASDAQ: ANGO) reported Q4 EPS of $0.19, $0.03 better than the analyst estimate of $0.16. Revenue for the quarter came in at $86.9 million versus the consensus estimate of $90.74 million.

“The quarter, and year, reflect a commitment to strengthening our business, improving our core operational efficiency and making strategic decisions that will enable long-term, sustainable top-line growth as we outlined in our recent Investor Day, held in April,” said Jim Clemmer, President and Chief Executive Officer of AngioDynamics. “Over the course of the year, we have worked hard to become a profitable, efficiently run operating company. We ended the year with record high Adjusted EPS of $0.73 and free cash flow of more than $52 million. These are important measures as we look at opportunities to spur growth in fiscal year 2018 and beyond.”

The Company issued its FY2018 financial guidance affirming a net sales range of $352 to $359 million, adjusted earnings per share (EPS) of $0.64 to $0.68 and free cash flow of greater than $35 million.

For earnings history and earnings-related data on AngioDynamics (ANGO) click here.

You May Also Be Interested In

• FedEx falls 4% as FY2027 profit forecast misses expectations despite Q4 beat
• Cerebras Systems posts 94% revenue jump, announces OpenAI deal
• CVG to join Russell 2000 and Russell 3000 indexes June 26